Modibo Diallo,Laura Salavessa,Benoit Arveiler et al.
Modibo Diallo et al.
Albinism classically encompasses several forms: oculocutaneous (OCA), ocular (OA1 and Foveal hypoplasia optic nerve decussation defect anterior segment dysgenesis syndrome [FHONDA]), and syndromic (Hermansky-Pudlak syndrome [HPS], Chediak-H...
Fanny Morice-Picard,Modibo Diallo,Benoit Arveiler
Fanny Morice-Picard
Although it has been described for a long time, albinism remains poorly understood in many aspects. The clinical presentation is very different between subtypes of the disease and even within a single subtype. The monogenic nature of the di...
Maxence Rateaux,Dominique Bremond-Gignac,Matthieu P Robert
Maxence Rateaux
Albinism is a heterogeneous disorder characterized by both dermatological and ophthalmological expressions. In ophthalmological practice, patients with albinism frequently present with nystagmus and reduced visual acuity, the diagnosis havi...
Cédric Mahiat,Jacques Cadranel,Vincent Fallet et al.
Cédric Mahiat et al.
Immune checkpoint inhibitor-related pneumonitis (ICI-P) is an uncommon but serious immune-related adverse event, representing the leading cause of treatment-related mortality among patients receiving immune checkpoint inhibitors (ICIs). Pro...
Rakiba Belkhir,Marjolaine Gosset,Antoine Rousseau et al.
Rakiba Belkhir et al.
Background: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment but are associated with immune-related adverse events (irAEs), including sicca syndrome. This condition, characterized by ocular and ora...
Maria Ortega Abad,Ricardo Correa
Maria Ortega Abad
The use of immune checkpoint inhibitors in cancer therapy has increased throughout the years and will continue in the future. These drugs have shown groundbreaking survival improvements in patients with different types of cancer and are bei...
Davide Fattore,Giuseppe Lauletta,Cecile Pages et al.
Davide Fattore et al.
The use of immune checkpoint inhibitors (ICIs) has emerged as a transformative approach in the treatment of various malignancies. ICIs target immune regulatory pathways-specifically cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), prog...
Franck Carbonnel,Antoine Martin,Lysiane Marthey et al.
Franck Carbonnel et al.
Immune checkpoint inhibitors (ICI) have improved the prognosis of several cancers. ICI enhance T-cell activation, and therefore stimulate anti-cancer immunity, but also cause immune related adverse effects (irAE), including those affecting ...
Immunotherapy and the heart: understanding the cardiovascular risks of immune checkpoint inhibitors [0.03%]
免疫检查点抑制剂引起的心血管毒性：机制和风险因素
Maria Sol Andres,Maria Clara Llamedo,Sivatharshini Ramalingam et al.
Maria Sol Andres et al.
The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer therapy, offering improved survival outcomes in various malignancies. However, their use is associated with immune-related adverse events (irAEs), including severe ...
Lucile Regard,Nicolas Roche
Lucile Regard
Most patients with Chronic Obstructive Pulmonary Disease (COPD) can be managed effectively through standard therapeutic strategies. However, a significant proportion remains symptomatic, experiences recurrent exacerbations, or shows acceler...